Displaying 37 - 48 of 54
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
Cirrhosis & Complications
4

Grifols: Albumin: a disease-modifying agent in decompensated cirrhosis - Digital ILC 2020

View
Cirrhosis & Complications
4

Grifols: Albumin: a disease-modifying agent in decompensated cirrhosis - Digital ILC 2020

View
Cirrhosis & Complications
4

Grifols: Albumin: a disease-modifying agent in decompensated cirrhosis - Digital ILC 2020

View
Cirrhosis & Complications
4

Grifols: Albumin: a disease-modifying agent in decompensated cirrhosis - Digital ILC 2020

View
Displaying 37 - 48 of 54